MNTA - Momenta Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.60
-0.55 (-5.42%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close10.15
Open10.11
Bid9.27 x 800
Ask12.19 x 1400
Day's Range9.60 - 10.25
52 Week Range9.55 - 32.20
Volume498,201
Avg. Volume473,320
Market Cap946.67M
Beta (3Y Monthly)2.23
PE Ratio (TTM)N/A
EPS (TTM)-2.07
Earnings DateAug 2, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.75
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Momenta Pharmaceuticals Announces Date of Second Quarter 2019 Financial Results Conference Call and Webcast

    Management will host a conference call on August 2, 2019 at 8:30 a.m. ET to discuss these results and provide an update on the company. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com. Momenta Pharmaceuticals is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases and advancing its late stage biosimilar portfolio.

  • GlobeNewswirelast month

    Momenta Pharmaceuticals Announces Settlement Agreement with Amphastar Resolving Enoxaparin Sodium Injection Litigation

    Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Momenta, Sandoz AG and Amphastar Pharmaceuticals (the “parties”) have executed a mutually agreeable settlement agreement resolving all pending litigation between the parties related to enoxaparin sodium injection. “We are very pleased to have reached a comprehensive resolution with Amphastar resolving all of our outstanding litigation,” said Craig Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals. Under terms of the settlement, the parties jointly requested the U.S. District Court for the District of Massachusetts (the “District Court”) to vacate the 2017 patent judgment relating to the parties.

  • Markitlast month

    See what the IHS Markit Score report has to say about Momenta Pharmaceuticals Inc.

    Momenta Pharmaceuticals Inc NASDAQ/NGS:MNTAView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for MNTA with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding MNTA are favorable, with net inflows of $2.18 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Did You Manage To Avoid Momenta Pharmaceuticals's (NASDAQ:MNTA) 47% Share Price Drop?
    Simply Wall St.last month

    Did You Manage To Avoid Momenta Pharmaceuticals's (NASDAQ:MNTA) 47% Share Price Drop?

    The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...

  • GlobeNewswire2 months ago

    Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 40th Annual Global Healthcare Conference

    Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Craig Wheeler, President and CEO, will present at the Goldman Sachs 40th Annual Global Healthcare Conference.  The presentation is scheduled for Tuesday, June 11, 2019 at 8:40 a.m. PT (11:40 a.m. ET). A webcast of the presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com. A replay of the presentation will be posted on the Momenta website approximately one hour after the event.

  • Momenta (MNTA) Down 16.6% Since Last Earnings Report: Can It Rebound?
    Zacks2 months ago

    Momenta (MNTA) Down 16.6% Since Last Earnings Report: Can It Rebound?

    Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of MNTA earnings conference call or presentation 2-May-19 12:30pm GMT

    Q1 2019 Momenta Pharmaceuticals Inc Earnings Call

  • GlobeNewswire2 months ago

    Momenta Pharmaceuticals to Webcast Presentation at the 2019 Bank of America Merrill Lynch Healthcare Conference

    Momenta Pharmaceuticals, Inc. (MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Craig Wheeler, President and CEO, will present at the 2019 Bank of America Merrill Lynch Healthcare Conference.  The presentation is scheduled for Thursday, May 16, 2019 at 9:20 a.m. PT (12:20 p.m. ET). A webcast of the presentation will be available live on the “Investors” section of the company’s website located at www.momentapharma.com.  A replay of the presentation will be posted on the Momenta website approximately one hour after the event. Momenta is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases and advancing its late stage biosimilar portfolio.

  • Momenta Pharmaceuticals Wants to Be the "Humira of the FcRn Space"
    Motley Fool2 months ago

    Momenta Pharmaceuticals Wants to Be the "Humira of the FcRn Space"

    It's going to take a few years to get there.

  • Hedge Funds Have Never Been This Bullish On Momenta Pharmaceuticals, Inc. (MNTA)
    Insider Monkey3 months ago

    Hedge Funds Have Never Been This Bullish On Momenta Pharmaceuticals, Inc. (MNTA)

    How do we determine whether Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]

  • Momenta Pharmaceuticals Inc (MNTA) Q1 2019 Earnings Call Transcript
    Motley Fool3 months ago

    Momenta Pharmaceuticals Inc (MNTA) Q1 2019 Earnings Call Transcript

    MNTA earnings call for the period ending March 31, 2019.

  • Momenta Pharmaceuticals (MNTA) Reports Q1 Loss, Misses Revenue Estimates
    Zacks3 months ago

    Momenta Pharmaceuticals (MNTA) Reports Q1 Loss, Misses Revenue Estimates

    Momenta (MNTA) delivered earnings and revenue surprises of -2.22% and -57.08%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Momenta: 1Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 46 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire3 months ago

    Momenta Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results

    — M281 Phase 2 trials in MG and HDFN active and enrolling patients — — Data supporting M281’s mechanism in HDFN, as first anti-FcRn antibody to inhibit maternal-fetal IgG.

  • Momenta Pharmaceuticals (MNTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks3 months ago

    Momenta Pharmaceuticals (MNTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire3 months ago

    Momenta Pharmaceuticals Announces Date of First Quarter 2019 Financial Results Conference Call and Webcast

    Management will host a conference call on May 2, 2019 at 8:30 a.m. ET to discuss these results and provide an update on the company. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com. Momenta is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases.

  • GlobeNewswire4 months ago

    New Research Coverage Highlights American International Group, Fox Factory Holding, Momenta Pharmaceuticals, Mercer International, Endurance International Group, and Addus HomeCare — Consolidated Revenues, Company Growth, and Expectations for 2019

    NEW YORK, March 29, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.

  • GlobeNewswire4 months ago

    Momenta Pharmaceuticals Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019

    CAMBRIDGE, Mass., March 28, 2019 -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to.

  • Novartis (NVS) Receives FDA Approval for MS Drug Mayzent
    Zacks4 months ago

    Novartis (NVS) Receives FDA Approval for MS Drug Mayzent

    Novartis (NVS) obtains FDA approval for Mayzent for the treatment of relapsing forms of MS.